• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

    54.80 -0.61 (-1.11%)
    Streaming Delayed Price Updated: 9:46 AM EDT, Apr 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Xenon Pharmaceuticals Inc. - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    4 Analysts Have This to Say About Xenon Pharmaceuticals ↗
     
    Via Benzinga
    News headline image
    Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today ↗
    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542... 
    Via Benzinga
    News headline image
    Xenon Pharmaceuticals: Q3 Earnings Insights ↗
     
    Via Benzinga
    News headline image
    Earnings Outlook For Xenon Pharmaceuticals ↗
     
    Via Benzinga
    News headline image
    Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Announces Proposed Public Offering
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    News headline image
    Xenon Pharma's Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst ↗
    Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20... 
    Via Benzinga
    News headline image
    Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
    Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results. 
    Via Benzinga
    News headline image
    The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring ↗
    The company's epilepsy drug also showed promise as a depression treatment. 
    Via Investor's Business Daily
    News headline image
    What's Going On With Neurology-Focused Xenon Pharmaceuticals' Stock Today? ↗
    Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of... 
    Via Benzinga
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Near the Top of Equities by Percentage Gain on 11/27
    Via Investor Brand Network
    News headline image
    Ituran Location and Control Posts Q3 Results, Joins Crown Castle, Shopify And Other Big Stocks Moving Higher On Monday ↗
    U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday. Shares of Ituran Location and Control Ltd. (NASDAQ: ITRN) gained during Monday’s session after the company... 
    Via Benzinga
    Topics Stocks
    News headline image
    Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
    Conference call today at 8:30 am ET 
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Why Is Neurocrine Biosciences Stock Trading Lower Today? ↗
    Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)  
    Via Benzinga
    News headline image
    Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
    Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency 
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 8, 2023 ↗
    Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
    Via Benzinga
    News headline image
    Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Making Surprising Moves in Tuesday Session
    Via Investor Brand Network
    News headline image
    Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
    Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET 
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.